Riluzole (Rilutek, Tiglutik)
Other Medications · Approved since 1995
Description
Riluzole is a glutamate release inhibitor and sodium channel blocker originally developed for amyotrophic lateral sclerosis (ALS) that is being repurposed in colorectal cancer as a neuroprotective agent. In CRC treatment, riluzole is primarily used off-label to prevent oxaliplatin-induced peripheral neuropathy, a dose-limiting side effect of FOLFOX-based chemotherapy regimens. The drug has also been explored for managing cancer-related cognitive impairment and as a combination agent with standard CRC therapies like mFOLFOX6 and bevacizumab.
Mechanism of Action
Riluzole inhibits glutamate release from presynaptic nerve terminals and blocks voltage-gated sodium channels, reducing neuronal excitotoxicity. By modulating glutamate neurotransmission and protecting against oxidative stress-induced neuronal damage, riluzole may help preserve nerve function during neurotoxic chemotherapy treatments.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Rilutek, Tiglutik |
| Category | Other Medications |
 Status | Off-label |
 EMA Status | EMA Approved |
 Spain Access | Hospital use off-label in CRC |
| Administration | Oral |
| Year Approved | 1995 |
| Clinical Trials | 4 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.